Results of a phase II study involving Duvelisib for treatment of relapsed indolent lymphomas.
Home / Resource Library / DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Results of a phase II study involving Duvelisib for treatment of relapsed indolent lymphomas.